Sandoz is a world leader in generic pharmaceuticals, finding innovative ways to making medicines affordable and accessible to more than 90 percent of the world’s population.Learn more about our company
Visions and Values
Increasing access to medicines against chronic diseases
May 24, 2016
Sandoz, a Novartis division and the global leader in biosimilars, announced today that the European Medicines Agency has accepted their Marketing Authorization Application for a biosimilar to Roche’s EU-licensed MabThera® (rituximab). Rituximab is a monoclonal antibody that is used ......
Our people are our greatest resource. We are always looking for new colleagues to share in our commitment to make the world a healthier place.Learn more about careers at Sandoz
Watch our videos to discover more about the world of Sandoz and the generics market.Visit our video gallery to watch the latest episode